Cochrane · systematic review · CD005590
Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
Stern, A, Green, H, Paul, M, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 50%Moderate 2 · 50%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
TMP/SMX versus placebo, no treatment or non‐PCP drug for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
Population: patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Documented PCP infections Clinical and microbiological criteria TMP/SMX vs placebo, no treatment or non‐PCP drug | no estimate extracted | 10 studies · 1000 participants | Moderate Downgraded: risk of bias, inconsistency |
All cause mortality ‐ TMP/SMX versus placebo or no treatment TMP/SMX vs placebo, no treatment or non‐PCP drug | RR 0.58 [0.17, 2] | 4 studies · 461 participants | Low Downgraded: imprecision |
PCP‐related mortality Clinical only TMP/SMX vs placebo, no treatment or non‐PCP drug | RR 0.17 [0.03, 0.94] | 9 studies · 886 participants | Low Downgraded: risk of bias |
Adverse events: severe adverse events requiring treatment discontinuation ‐ TMP/SMX versus placebo or no treatment Clinical and laboratory criteria and treatment discontinuations TMP/SMX vs placebo, no treatment or non‐PCP drug | RR 0.28 [0.05, 1.7] | 5 studies · 530 participants | Moderate |